


Financial Data Highlights

- Sales Revenue (left axis)
- Core Operating Income (right axis)
- Core Operating Income to Sales Revenue


¥92.8 billion (Core Operating Income) vs. FY2021 **-60.5%** ↓



Sales revenue increased by 130.0 billion yen from the previous fiscal year, mainly due to the difference in translation into Japanese yen resulting from the yen's depreciation. On the other hand, core operating income decreased 142.0 billion yen from the previous fiscal year, mainly due to worsening terms of trade in the Essential Chemicals & Plastics Sector due to soaring raw material and fuel prices, and the end of the exclusive sales period of LATUDA® in the Pharmaceuticals Sector in the United States.

- Net Income Attributable to Owners of the Parent (left axis)
- Basic Earnings per Share (right axis)


¥7.0 billion (Net Income Attributable to Owners of the Parent) vs. FY2021 **-95.7%** ↓



In addition to the decrease in core operating income, net income attributable to owners of the parent decreased by 155.1 billion yen from the previous year to 7.0 billion yen, mainly due to a large impairment loss recorded in the Pharmaceuticals Sector during the year.

- Total Assets (left axis)
- Asset Turnover (right axis)


¥4,165.5 billion (Total Assets) vs. FY2021 **-3.3%** ↓



Total assets decreased by 142.6 billion yen from the end of the previous fiscal year to 4,165.5 billion yen, mainly due to a decrease in goodwill and intangible assets resulting from impairment.

- Interest-bearing Liabilities (left axis)
- D/E Ratio^{*1} (right axis)
- Net D/E Ratio^{*2} (right axis)

1,461.4 billion (Interest-bearing Liabilities) vs. FY2021 **+8.2%** ↑




Interest-bearing liabilities increased 110.9 billion yen from the previous year, mainly due to increased borrowings in the Pharmaceuticals Sector. On the other hand, the D/E ratio and net D/E ratio increased due to a decrease in both equity attributable to owners of the parent company and total equity, mainly as a result of Myovant becoming a wholly owned subsidiary.

*1 D/E ratio=Interest-bearing liabilities/Total equity

*2 Net D/E Ratio=Net Interest-bearing Liabilities (Interest-bearing Liabilities-Cash and Cash Equivalents)/Equity attributable to Owners of the Parent

■ Cash Flows from Operating Activities
■ Cash Flows from Investing Activities
● Free Cash Flow

¥92.2 billion (Free Cash Flow) vs. FY2021
+35.9 billion ↑




Cash flows from operating activities decreased 60.1 billion yen mainly due to a decrease in income before income taxes, despite an increase in non-cash profit/loss items such as impairment losses and a decrease in working capital.

Cash flows from investing activities decreased by 96.0 billion yen due to proceeds from collection of loan receivables and proceeds from sales and redemption of other financial assets. As a result, free cash flow increased by 35.9 billion yen to 92.2 billion yen.

● ROE ● ROI


0.6% (ROE) vs. FY2021
-13.9 pt ↓
-1.3% (ROI) vs. FY2021
-7.9 pt ↓



Both ROE and ROI were significantly lower than the previous year due to the significant deterioration in net income for the period.

■ Cash Dividends per Share (left axis)
● Dividend Payout Ratio (right axis)

421.2% (Dividend Payout Ratio) vs. FY2021
+397.0 pt ↑




For the year under review, the Company declared an annual dividend of 18 yen per share. Due to the impact of the decrease in net income attributable to owners of the parent, the dividend payout ratio was 421.2%.

Research and Development Expenses (left axis)

■ Essential Chemicals & Plastics ■ Energy & Functional Materials
■ IT-related Chemicals ■ Health & Crop Sciences ■ Pharmaceuticals ■ Others

● Ratio of R&D Expenses to Sales Revenue (right axis)

¥195.6 billion (Research and Development Expenses) vs. FY2021
+11.8% ↑



R&D expenses increased by 20.7 billion yen from the previous year to 195.6 billion yen, mainly due to the difference in translation due to the weaker yen in the Pharmaceuticals Sector.